Skip to content
Research Article Open access CC BY 3.0

Prodrugs-Current and Future Drug Development Strategy

Rafik Karaman

International Journal of Medical and Pharmaceutical Case Reports · pp. 58–63 · Published 26 Aug 2014

10.9734/IJMPCR/2014/13183

Abstract

The focus of traditional prodrug approach was on altering various physiochemical parameters, whereas the current modern computational approach considers designing prodrugs through attaching appropriate linkers with drugs having poor bioavailability which upon exposure to physiological environments release the parent active drugs in a programmable (controlled) manner resulting in an improvement of their bioavailability. With the possibility of designing prodrugs with different linkers, the release rate of the parent active drugs can be controlled. The future of prodrug technology is exciting and yet challenging. Advances must be made in understanding the chemistry of many organic reactions that can be effectively utilized to enable the development of more types of prodrugs. The understanding of organic reaction mechanisms of certain processes, particularly intramolecular reactions, will be the next major milestone in this field. It is envisioned that the future of prodrug technology holds the ability to create safe and efficacious delivery of a wide range of active small molecules and biotherapeutics. This goal can be achieved using computational chemistry methods such as ab initio, semi-empirical and density functional theory (DFT), and molecular mechanics (MM) to calculate physicochemical and molecular properties of current marketed drugs suffer low bioavailability or/and unpleasant taste or odor.

Prodrugs intramolecular processes DFT ab initio targeted prodrugs physicochemical properties ADME computational chemistry.

References (36)

  1. 1 The price of innovation: new estimates of drug development costs [DOI]
  2. 2 Prodrugs: design and clinical applications [DOI]
  3. 3 Lessons Learned from Marketed and Investigational Prodrugs [DOI]
  4. 4 The Value of Improving the Productivity of the Drug Development Process [DOI]
  5. 5 Prodrugs [DOI]
  6. 6 Prodrug Approaches for Enhancing the Bioavailability of Drugs with Low Solubility [DOI]
  7. 7 Prodrugs: bridging pharmacodynamic/pharmacokinetic gaps [DOI]
  8. 8 Targeted prodrugs in oral drug delivery: the modern molecular biopharmaceutical approach [DOI]
  9. 9 Analysis of Menger’s ‘spatiotemporal hypothesis’ [DOI]
  10. 10 Computer-assisted design for paracetamol masking bitter taste prodrugs [DOI]
  11. 11 Research Article: Computer‐Assisted Design of Pro‐drugs for Antimalarial Atovaquone [DOI]
  12. 12 Prodrugs for masking bitter taste of antibacterial drugs—a computational approach [DOI]
  13. 13 Prodrugs of aza nucleosides based on proton transfer reaction [DOI]
  14. 14 The efficiency of proton transfer in Kirby’s enzyme model, a computational approach [DOI]
  15. 15 Cleavage of Menger’s aliphatic amide: A model for peptidase enzyme solely explained by proximity orientation in intramolecular proton transfer [DOI]
  16. 16 Prodrugs of Acyclovir – A Computational Approach [DOI]
  17. 17 The effective molarity (EM) puzzle in proton transfer reactions [DOI]
  18. 18 A computational analysis of intramolecularity in proton transfer reactions [DOI]
  19. 19 Computational‐Aided Design for Dopamine Prodrugs Based on Novel Chemical Approach [DOI]
  20. 20 A general equation correlating intramolecular rates with ‘attack’ parameters: distance and angle [DOI]
  21. 21 Analyzing Kirby’s amine olefin—a model for amino acid ammonia lyases [DOI]
  22. 22 The effective molarity (EM) – A computational approach [DOI]
  23. 23 Analyzing the efficiency in intramolecular amide hydrolysis of Kirby’s N-alkylmaleamic acids – A computational approach [DOI]
  24. 24 Computer-assisted design for atenolol prodrugs for the use in aqueous formulations [DOI]
  25. 25 Proximity vs. strain in intramolecular ring-closing reactions [DOI]
  26. 26 Analyzing the efficiency of proton transfer to carbon in Kirby’s enzyme model—a computational approach [DOI]
  27. 27 The role of proximity orientation in intramolecular proton transfer reactions [DOI]
  28. 28 Prodrugs of fumarate esters for the treatment of psoriasis and multiple sclerosis—a computational approach [DOI]
  29. 29 Design of prodrugs
  30. 30 The Impact of Genomics on Drug Discovery [DOI]
  31. 31 Proteomics in drug discovery [DOI]
  32. 32 The future of prodrugs – design by quantum mechanics methods [DOI]
  33. 33 Design, synthesis and in vitro kinetic study of tranexamic acid prodrugs for the treatment of bleeding conditions [DOI]
  34. 34 Computationally designed prodrugs of statins based on Kirby’s enzyme model [DOI]
  35. 35 http://www.omicsgroup.org/journals/insulin-as-therapeutic-agent-against-alzheimers-disease-2169-0138.1000e112.php?aid=9763 [DOI]
  36. 36 Analyzing Kemp’s amide cleavage: A model for amidase enzymes [DOI]

Cited by 5

Introduction

Vivekkumar K. Redasani, Sanjay B. Bari · Prodrug Design · 2015

Current Research on Pro-drug Therapies for Parkinson's and Alzheimer's Disease

Cui Huo, Lei Wu, Zhiqiang Jiang · Medicinal Chemistry · 2022

Showing 2 of 5 known citations — external sources report more than can currently be individually listed.

Related research

Article metrics

Real usage data collected on this platform.

57

Page views

0

PDF downloads

10

Outbound clicks

5

Citations

Views over time

Views by country

Approximate, from request IP at view time — not citizenship or institution. Countries with fewer than 5 views are grouped as "Other".

Traffic sources

Referring site, by host.

Views and downloads exclude known bots/crawlers. Citations combines this platform's own DOI-resolved index with each external source's own reported total — see Cited by above for individually listed citing works. Last refreshed 0 seconds ago.